|Videos|February 19, 2018

Pseudomonas aeruginosa: Current & Future Treatment Options

Marin H. Kollef, MD, discusses treatment options for Pseudomonas aeruginosa.

Marin H. Kollef, MD, professor of medicine and Virginia E. & Sam J. Golman chair of the Respiratory Intensive Care department of Washington University School of Medicine, discusses the current treatment options for Pseudomonas aeruginosa—piperacillin-tazobactam being the drug that is most commonly used in the United States. Dr. Kollef highlights other drugs that are also used for treatment, including cefcapene, aminoglycosides, and carbapenems. He also discusses 3 newer drugs available for the treatment of Pseudomonas infections.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.